Hematopoietic stem cell transplant in adults with acute lymphoblastic leukemia: the present state

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Expert Review of Hematology

• Publication date

  2018-02-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/17474086.2018.1433030PMID 29376437
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Acute Lymphoblastic Leukemia in Children and Adolescents

  2018cited by this paper
• Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT

  2017cited by this paper
• Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia.

  2017cited by this paper
• The evolving role of chemotherapy and hematopoietic cell transplants in Ph-positive acute lymphoblastic leukemia in adults

  2017cited by this paper
• Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

  2017cited by this paper
• Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults.

  2017cited by this paper
• Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia

  2017cited by this paper
• Philadelphia-Like Acute Lymphoblastic Leukemia in Adults

  2017cited by this paper
• Adults with Philadelphia chromosome–like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis

  2017cited by this paper
• Cancer statistics, 2017

  2017cited by this paper
• Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study.

  2017cited by this paper
• Comparing outcomes of matched related donor and matched unrelated donor hematopoietic cell transplants in adults with B‐Cell acute lymphoblastic leukemia

  2017cited by this paper
• High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.

  2017cited by this paper
• Reduction of Relapse after Unrelated Donor Stem Cell Transplantation by KIR-Based Graft Selection

  2017cited by this paper
• Haploidentical transplantation compared with matched sibling and unrelated donor transplantation for adults with standard‐risk acute lymphoblastic leukaemia in first complete remission

  2017cited by this paper
• Haploidentical versus Matched-Sibling Transplant in Adults with Philadelphia-Negative High-Risk Acute Lymphoblastic Leukemia: A Biologically Phase III Randomized Study

  2016cited by this paper
• Comparison of Total Body Irradiation-Based with Intravenous Busulfan-Based Chemotherapy-Only Conditioning Regimens for Myeloablative Hematopoietic Cell Transplantation (HCT) in Adults with Acute Lymphoblastic Leukemia

  2016cited by this paper
• Pediatric‐inspired therapy compared to allografting for Philadelphia chromosome‐negative adult ALL in first complete remission

  2016cited by this paper
• Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.

  2016cited by this paper
• Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.

  2015cited by this paper
• New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia

  2015cited by this paper
• Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia.

  2015cited by this paper
• Haploidentical hematopoietic transplantation from KIR ligand-mismatched donors with activating KIRs reduces nonrelapse mortality.

  2015cited by this paper
• Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia.

  2015cited by this paper
• Long-Term Outcomes after Blinatumomab Treatment: Follow-up of a Phase 2 Study in Patients (Pts) with Minimal Residual Disease (MRD) Positive B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)

  2015cited by this paper
• Improving results of autologous stem cell transplantation for Philadelphia-positive acute lymphoblastic leukaemia in the era of tyrosine kinase inhibitors: a report from the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation.

  2014influential reference
• Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance)

  2014cited by this paper
• Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia.

  2014cited by this paper
• Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.

  2014cited by this paper
• UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.

  2014cited by this paper
• Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.

  2014cited by this paper
• KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL.

  2014cited by this paper
• Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia

  2014cited by this paper
• Survival improvement by decade of patients aged 0–14 years with acute lymphoblastic leukemia: a SEER analysis

  2014cited by this paper
• Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission: a comparison with allografts from adult unrelated donors

  2014cited by this paper
• Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031

  2014cited by this paper
• Evidence for a GVL effect following reduced-intensity allo-SCT in ALL: a British Society of Blood and Marrow Transplantation study

  2013cited by this paper
• Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1-positive acute lymphoblastic leukemia

  2013cited by this paper
• Evidence for a GVL effect following reduced-intensity allo-SCT in ALL: a British Society of Blood and Marrow Transplantation study

  2013cited by this paper
• Reduced-intensity vs myeloablative conditioning allogeneic hematopoietic SCT for patients aged over 45 years with ALL in remission: a study from the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT)

  2013cited by this paper
• Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis.

  2013cited by this paper
• Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes.

  2012cited by this paper
• Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial

  2012cited by this paper
• Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies.

  2012cited by this paper
• BU- vs TBI-based conditioning for adult patients with ALL

  2011cited by this paper
• Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia (ALL) in first complete remission.

  2011influential reference
• Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia.

  2010cited by this paper
• Management of adult patients with acute lymphoblastic leukemia in first complete remission

  2010cited by this paper
• Minimal residual disease is a significant predictor of treatment failure in non T‐lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993

  2010cited by this paper
• Prognostic factors in adult acute lymphoblastic leukaemia

  2010cited by this paper
• Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation.

  2010cited by this paper
• The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission.

  2010cited by this paper
• Dasatinib followed by second allogeneic hematopoietic stem cell transplantation for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia after the first transplantation

  2010cited by this paper
• Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation.

  2010cited by this paper
• Allogeneic stem cell transplantation for adult Philadelphia chromosome-negative acute lymphocytic leukemia: comparable survival rates but different risk factors between related and unrelated transplantation in first complete remission.

  2010cited by this paper
• Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993.

  2009cited by this paper
• The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation.

  2009cited by this paper
• Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.

  2009cited by this paper
• Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia.

  2009cited by this paper
• Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia

  2009cited by this paper
• Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).

  2009cited by this paper
• Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia.

  2009cited by this paper
• Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study.

  2009cited by this paper
• Status of minimal residual disease after induction predicts outcome in both standard and high‐risk Ph‐negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4‐2002 MRD Study

  2008cited by this paper
• A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation.

  2008cited by this paper
• Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.

  2007cited by this paper
• Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study.

  2007cited by this paper
• Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia.

  2007cited by this paper
• Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial

  2007cited by this paper
• Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high‐risk acute lymphoblastic leukemia

  2006cited by this paper
• A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission.

  2006cited by this paper
• In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: fin

  2006cited by this paper
• Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia.

  2006cited by this paper
• Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

  2005cited by this paper
• Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993.

  2005cited by this paper
• Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial.

  2005cited by this paper
• Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia.

  2004cited by this paper
• Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission.

  2004cited by this paper
• Acute lymphoblastic leukemia.

  2004cited by this paper
• Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial.

  2004influential reference
• Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia.

  2004cited by this paper
• Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value.

  2003cited by this paper
• Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial.

  2002cited by this paper
• Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia.

  2002cited by this paper
• Clinical Observations, Interventions, and Therapeutic Trials

  2002cited by this paper
• Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.

  2000cited by this paper
• Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87.

  2000cited by this paper
• Cataracts after total body irradiation and bone marrow transplantation in patients with acute leukemia in complete remission: a study of the European Group for Blood and Marrow Transplantation.

  1998cited by this paper
• A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.

  1995cited by this paper
• Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia.

  1994cited by this paper
• Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission.

  1993cited by this paper
• Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. The French Group on Therapy for Adult Acute Lymphoblastic Leukemia.

  1993cited by this paper
• A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study.

  1993cited by this paper
• Radiation-free preparation for allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia.

  1992cited by this paper
• Conditioning for allogeneic marrow transplantation in patients with lymphohematopoietic malignancies without the use of total body irradiation.

  1992cited by this paper
• Cancer statistics

  1989cited by this paper
• Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts.

  1979cited by this paper

• Truncated form of human CD19 antigen as a suicide gene to control T-cell alloreactivity: ∆CD19

  2025cites this paper
• Treatment Approaches for Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

  2025cites this paper
• Efficacy and Safety of Total Body Irradiation versus Chemotherapy Conditioning for Hematopoietic Stem Cell Transplant in Adult Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis

  2024cites this paper
• CAR-T cell a potential platform for cancer therapy

  2024cites this paper
• Haematopoietic Stem Cell Transplantation in Adolescents and Young Adults With Acute Lymphoblastic Leukaemia: Special Considerations and Challenges

  2022cites this paper
• Haploidentical Versus Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

  2022cites this paper
• Systematic review and pooled analysis of survival outcomes in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia who have undergone haematopoietic stem cell transplant.

  2022influential citation
• Pretransplant Consolidation Therapies Improve the Outcome of Myeloablative Allogeneic Transplantation in Adults with Ph-negative Acute Lymphoblastic Leukemia.

  2022cites this paper
• Endocan in Acute Leukemia: Current Knowledge and Future Perspectives

  2022cites this paper
• Improvements in allogeneic hematopoietic cell transplantation outcomes for adults with ALL over the past 3 decades

  2022cites this paper
• CD7 CAR T bridging to allo‐HSCT in R/R T‐ALL: A case report

  2022cites this paper
• Isolated Renal Relapse in a Post-Allogenic Transplant Adult Patient With Acute Lymphoblastic Leukemia

  2022cites this paper
• Gene Expression and Survival of Acute Lymphoblastic Leukemia Cells After Allogeneic Transplant

  2021cites this paper
• A Review of Infections After Hematopoietic Cell Transplantation Requiring PICU Care: Transplant Timeline Is Key

  2021cites this paper
• Clinical outcomes of patients with acute lymphoblastic leukemia receiving the hyper-CVAD regimen and assessment of the risk of hepatitis flares due to hepatitis B virus reactivation after chemotherapy

  2021cites this paper
• CAR-T after Stem Cell Transplantation in B-Cell Lymphoproliferative Disorders: Are They Really Autologous or Allogenic Cell Therapies?

  2021cites this paper
• Anti-CD19 CAR-T cell therapy bridge to HSCT decreases the relapse rate and improves the long-term survival of R/R B-ALL patients: a systematic review and meta-analysis

  2021cites this paper
• Cytomegalovirus prophylaxis using low-dose valganciclovir in patients with acute leukemia undergoing allogeneic hematopoietic stem-cell transplantation

  2021cites this paper
• Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL

  2021cites this paper
• Mechanisms of Immune Evasion in Acute Lymphoblastic Leukemia

  2021cites this paper
• Features of nutritional support during stem cell transplantation

  2020cites this paper
• Comparing the outcomes between TMLI and non-TMLI conditioning regimens for adult high-risk acute lymphoblastic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: a single-center experience

  2020cites this paper
• The use of methotrexate, vincristine, L-asparaginase and dexamethasone for salvaging adult acute lymphoblastic leukemia and lymphoma: a real-life experience

  2019cites this paper
• Haploidentical transplant in adult patients with acute lymphoblastic leukemia in Argentina: a comparison with matched related and unrelated donors

  2019cites this paper